Interstitial Lung Disease News

Among hospitalized patients with various pulmonary conditions, living in a low socioeconomic status area heightened the odds for 30-day mortality and readmission, according to results published in Annals of the American Thoracic Society.

A tool that includes age, BMI, two lung function measures and a diagnosis of idiopathic pulmonary fibrosis can predict new-onset exertional and resting hypoxemia in fibrotic interstitial lung disease, according to study results.

Patients with idiopathic pulmonary fibrosis had less lung function decline with an oral c-Jun N-terminal kinase 1, or JNK, inhibitor vs. placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.

Among patients with idiopathic pulmonary fibrosis, lung function decline was comparable between 52-week zinpentraxin alfa treatment and placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.

Race-specific vs. race-neutral lung function equations misclassified more patients with pulmonary fibrosis eligible for trials, therapy and transplantation referral, according to results published in Annals of the American Thoracic Society.

A blood test was capable of distinguishing sarcoidosis from other respiratory diseases using disease-specific antigen biomarkers/epitopes, according to results published in American Journal of Respiratory and Critical Care Medicine.

Among patients with idiopathic pulmonary fibrosis, higher microbial diversity in the mouth negatively impacted lung function, according to results published in American Journal of Respiratory and Critical Care Medicine.

Among patients with progressive pulmonary fibrosis, taking nintedanib for 52 weeks lowered the degree of worsened dyspnea, fatigue and cough compared with placebo, according to results published in European Respiratory Journal.

Increasing health care worker awareness of interstitial lung diseases can have a major impact on the timing of this diagnosis and receipt of treatment for suffering patients.

Receiving a 5 mg dose of controlled-release morphine twice daily for 14 days lowered objective cough frequency in patients with idiopathic pulmonary fibrosis, according to results published in The Lancet Respiratory Medicine.